186 related articles for article (PubMed ID: 26631911)
1. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.
Leitner NR; Witalisz-Siepracka A; Strobl B; Müller M
Cytokine; 2017 Jan; 89():209-218. PubMed ID: 26631911
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity.
Strobl B; Stoiber D; Sexl V; Mueller M
Front Biosci (Landmark Ed); 2011 Jun; 16(9):3214-32. PubMed ID: 21622231
[TBL] [Abstract][Full Text] [Related]
3. Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis.
Hainzl E; Stockinger S; Rauch I; Heider S; Berry D; Lassnig C; Schwab C; Rosebrock F; Milinovich G; Schlederer M; Wagner M; Schleper C; Loy A; Urich T; Kenner L; Han X; Decker T; Strobl B; Müller M
J Immunol; 2015 Nov; 195(10):5011-24. PubMed ID: 26432894
[TBL] [Abstract][Full Text] [Related]
4. Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent.
Li Z; Gakovic M; Ragimbeau J; Eloranta ML; Rönnblom L; Michel F; Pellegrini S
J Immunol; 2013 Mar; 190(5):2335-44. PubMed ID: 23359498
[TBL] [Abstract][Full Text] [Related]
5. TYK2 kinase activity is required for functional type I interferon responses in vivo.
Prchal-Murphy M; Semper C; Lassnig C; Wallner B; Gausterer C; Teppner-Klymiuk I; Kobolak J; Müller S; Kolbe T; Karaghiosoff M; Dinnyés A; Rülicke T; Leitner NR; Strobl B; Müller M
PLoS One; 2012; 7(6):e39141. PubMed ID: 22723949
[TBL] [Abstract][Full Text] [Related]
6. The Atlantic salmon protein tyrosine kinase Tyk2: molecular cloning, modulation of expression and function.
Sobhkhez M; Hansen T; Iliev DB; Skjesol A; Jørgensen JB
Dev Comp Immunol; 2013 Dec; 41(4):553-63. PubMed ID: 23872231
[TBL] [Abstract][Full Text] [Related]
7. Tyk2-dependent bystander activation of conventional and nonconventional Th1 cell subsets contributes to innate host defense against Listeria monocytogenes infection.
Hashiguchi T; Oyamada A; Sakuraba K; Shimoda K; Nakayama KI; Iwamoto Y; Yoshikai Y; Yamada H
J Immunol; 2014 May; 192(10):4739-47. PubMed ID: 24729620
[TBL] [Abstract][Full Text] [Related]
8. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors.
Sohn SJ; Barrett K; Van Abbema A; Chang C; Kohli PB; Kanda H; Smith J; Lai Y; Zhou A; Zhang B; Yang W; Williams K; Macleod C; Hurley CA; Kulagowski JJ; Lewin-Koh N; Dengler HS; Johnson AR; Ghilardi N; Zak M; Liang J; Blair WS; Magnuson S; Wu LC
J Immunol; 2013 Sep; 191(5):2205-16. PubMed ID: 23894201
[TBL] [Abstract][Full Text] [Related]
9. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.
Sanda T; Tyner JW; Gutierrez A; Ngo VN; Glover J; Chang BH; Yost A; Ma W; Fleischman AG; Zhou W; Yang Y; Kleppe M; Ahn Y; Tatarek J; Kelliher MA; Neuberg DS; Levine RL; Moriggl R; Müller M; Gray NS; Jamieson CH; Weng AP; Staudt LM; Druker BJ; Look AT
Cancer Discov; 2013 May; 3(5):564-77. PubMed ID: 23471820
[TBL] [Abstract][Full Text] [Related]
10. Tyk2 is a therapeutic target for psoriasis-like skin inflammation.
Ishizaki M; Muromoto R; Akimoto T; Sekine Y; Kon S; Diwan M; Maeda H; Togi S; Shimoda K; Oritani K; Matsuda T
Int Immunol; 2014 May; 26(5):257-67. PubMed ID: 24345760
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
Fuchs S; Kaiser-Labusch P; Bank J; Ammann S; Kolb-Kokocinski A; Edelbusch C; Omran H; Ehl S
Eur J Immunol; 2016 Nov; 46(11):2639-2649. PubMed ID: 27615517
[TBL] [Abstract][Full Text] [Related]
12. Human tyk2 kinase deficiency: another primary immunodeficiency syndrome.
Watford WT; O'Shea JJ
Immunity; 2006 Nov; 25(5):695-7. PubMed ID: 17098200
[TBL] [Abstract][Full Text] [Related]
13. Potent and Selective Knockdown of Tyrosine Kinase 2 by Antisense Oligonucleotides.
Tran NV; Nguyen LTA; Lim KW; Phan AT
Immunohorizons; 2021 Feb; 5(2):70-80. PubMed ID: 33542028
[TBL] [Abstract][Full Text] [Related]
14. Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia.
Tavakoli Shirazi P; Eadie LN; Page EC; Heatley SL; Bruning JB; White DL
Cancer Lett; 2021 Aug; 512():28-37. PubMed ID: 33971281
[TBL] [Abstract][Full Text] [Related]
15. Partial impairment of cytokine responses in Tyk2-deficient mice.
Karaghiosoff M; Neubauer H; Lassnig C; Kovarik P; Schindler H; Pircher H; McCoy B; Bogdan C; Decker T; Brem G; Pfeffer K; Müller M
Immunity; 2000 Oct; 13(4):549-60. PubMed ID: 11070173
[TBL] [Abstract][Full Text] [Related]
16. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.
Minegishi Y; Saito M; Morio T; Watanabe K; Agematsu K; Tsuchiya S; Takada H; Hara T; Kawamura N; Ariga T; Kaneko H; Kondo N; Tsuge I; Yachie A; Sakiyama Y; Iwata T; Bessho F; Ohishi T; Joh K; Imai K; Kogawa K; Shinohara M; Fujieda M; Wakiguchi H; Pasic S; Abinun M; Ochs HD; Renner ED; Jansson A; Belohradsky BH; Metin A; Shimizu N; Mizutani S; Miyawaki T; Nonoyama S; Karasuyama H
Immunity; 2006 Nov; 25(5):745-55. PubMed ID: 17088085
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of Janus kinases.
Pesu M; Laurence A; Kishore N; Zwillich SH; Chan G; O'Shea JJ
Immunol Rev; 2008 Jun; 223():132-42. PubMed ID: 18613833
[TBL] [Abstract][Full Text] [Related]
18. A comparative proteome analysis links tyrosine kinase 2 (Tyk2) to the regulation of cellular glucose and lipid metabolism in response to poly(I:C).
Grunert T; Leitner NR; Marchetti-Deschmann M; Miller I; Wallner B; Radwan M; Vogl C; Kolbe T; Kratky D; Gemeiner M; Allmaier G; Müller M; Strobl B
J Proteomics; 2011 Nov; 74(12):2866-80. PubMed ID: 21787891
[TBL] [Abstract][Full Text] [Related]
19. TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis.
Gracey E; Hromadová D; Lim M; Qaiyum Z; Zeng M; Yao Y; Srinath A; Baglaenko Y; Yeremenko N; Westlin W; Masse C; Müller M; Strobl B; Miao W; Inman RD
J Clin Invest; 2020 Apr; 130(4):1863-1878. PubMed ID: 32149730
[TBL] [Abstract][Full Text] [Related]
20. TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
Turrubiartes-Martínez E; Bodega-Mayor I; Delgado-Wicke P; Molina-Jiménez F; Casique-Aguirre D; González-Andrade M; Rapado I; Camós M; Díaz-de-Heredia C; Barragán E; Ramírez-Orellana M; Aguado B; Figuera Á; Martínez-López J; Fernández-Ruiz E
Genes (Basel); 2020 Nov; 11(12):. PubMed ID: 33260630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
